Insider Sale by CFO

Vaseem Mahboob, Chief Financial Officer of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), disposed of a total of 18,188 common shares for $418,217 in three separate transactions between July 30 and August 3, 2026. The first transaction on July 30 involved the sale of 3,980 shares at a weighted‑average price of $22.7539 per share. On July 31, Mahboob sold an additional 8,817 shares at a weighted‑average price of $22.6091 per share. The final transaction on August 3 comprised 5,391 shares sold at a weighted‑average price of $23.8012 per share.

These transactions were classified as nondiscretionary sales undertaken to satisfy tax‑withholding obligations arising from the vesting and settlement of restricted stock units (RSUs). Following the reported sales, Mahboob directly beneficially owned 93,891 common shares of Kestra Medical Technologies.

Stock Performance and Market Context

Since the insider sales, Kestra Medical’s share price has appreciated to $28.02, reflecting a 74.6% total return over the past year. The company’s market capitalization stands at approximately $1.63 billion, and the stock is trading near its 52‑week high of $30.00.

Recent Financial Results

In the fiscal fourth quarter of 2026, Kestra Medical reported revenue of $28.64 million, representing a 66% year‑over‑year increase and surpassing the consensus estimate of $26.5 million. Despite the revenue growth, the company posted a loss of $0.67 per share, wider than the forecasted loss of $0.58 per share.

Analyst Reactions

Stifel reiterated a Buy rating with a price target of $30.00, citing strong growth. Wolfe Research raised its price target to $30.00, highlighting better‑than‑expected execution. JPMorgan initiated coverage with an Overweight rating, emphasizing the potential of Kestra’s ASSURE wearable cardioverter defibrillator. Conversely, Oppenheimer began coverage with a Perform rating, noting a large addressable market and ongoing market‑share gains.

Additional Context

The article notes that the information was generated with AI assistance and reviewed by an editor. No further regulatory or compliance actions were mentioned beyond the tax‑withholding rationale for the insider sales.